Financial Advisory

Achelous Partners is also well known for providing other corporate financial advisory services to complement and enhance our Mergers and Acquisitions work. Our team is highly sophisticated in corporate finance and valuation skills enabling us to provide our clients with the support they require to make a transaction happen. In the past, we have taken on financial advisory assignments in the following areas:

  • Accessing and evaluating sources of acquisition or merger financing through one of our network of partners involved in capital raising activities throughout the US, Europe and Australia
  • Restructurings, including a strategic review of whether to acquire, sell or divest
  • Providing Board and Management presentations conducting thorough, objective analyses of:
    • the environment affecting the company, including current trends in M&A, Private Equity, Hedge Funds, Debt and Equity markets
    • a universe mapping all of the competitors and potential M&A opportunities by industry, business model, region and other criteria
    • the benefits and risks of M&A vs Licensing/JVs/Collaborations
  • Providing tactical and financial advice on acquiring a strategic stake in public companies in domestic or international markets
  • Gaining unrealized value in listing in markets with more sophisticated investors and better financing alternatives, including listing on a US exchange via American Depository Receipts
  • Advising on creative strategic alternatives to maximize shareholder value
  • June 2017
    has been acquired by
    The undersigned acted as financial advisor to Coté Orphan, LLC
  • May 2017
    has been acquired by
    The undersigned acted as financial advisor to PharmaCell B.V.
  • April 2017
    has been acquired by
    The undersigned acted as financial advisor to Emergo Group, Inc.
  • April 2017
    has been acquired by
    The undersigned acted as financial advisor to Calbiotech, Inc.
  • January 2017
    has been acquired by
    The undersigned acted as financial advisor to BioControl Systems, Inc.
  • August 2016
    has been acquired by
    The undersigned acted as financial advisor to SPEware Corporation
  • July 2016
    has acquired
    The undersigned acted as financial advisor to Sharps Compliance Corp.
  • June 2016
    has been acquired by
    The undersigned acted as financial advisor to Cisbio Bioassays
  • December 2015
    has acquired
    The undersigned acted as financial advisor to Abzena plc
  • December 2015
    has acquired
    The undersigned acted as financial adviser to Sharps Compliance Corp.
  • October 2015
    has been acquired by
    The undersigned acted as financial advisor to Kinesis Pharma BV
  • August 2015
    has been acquired by
    The undersigned acted as financial advisor to DIAsource ImmunoAssays SA
  • July 2015
    has acquired
    The undersigned acted as financial advisor to Sharps Compliance Corp.
  • March 2015
    has acquired
    The undersigned acted as financial advisor to Ansell Limited
  • July 2014
    has been acquired by
    The undersigned acted as financial advisor to IBL International Holding BV
  • July 2014
    has been acquired by
    The undersigned served as financial advisor to Phlexglobal Limited
  • June 2014
    has been acquired by
    The undersigned served as financial advisors to Pharmalink Consulting
  • December 2013
    has acquired assets from
    The undersigned acted as advisor to Valeant Pharmaceuticals International
  • August 2013
    has been acquired by
    The undersigned acted as financial advisor to Kirkegaard & Perry Laboratories Inc
  • July 2013
    has been acquired by
    The undersigned acted as financial advisor to The Anson Group LLC
  • July 2013
    has signed a definitive agreement to sell its orthopedic implant assets and business to
    an Apax Partners company The undersigned acted as financial advisor to Austofix Group Limited
  • July 2013
    has been acquired by
    The undersigned acted as financial advisor to Kreatech Holding B.V.
  • July 2013
    has been acquired by
    USD$10,000,000
    The undersigned acted as financial advisor to Matrical Bioscience Inc
  • May 2013
    has been acquired by
    The undersigned acted as advisor to Triangle Biomedical Sciences Inc.
  • August 2012
    has been acquired by
    The undersigned acted as advisor to JSW Life Sciences GmbH
  • March 2012
    has acquired assets from
    US$164M plus up to US$20M in milestones
    The undersigned acted as advisor to Valeant Pharmaceuticals International
  • December 2011
    invests in
    The undersigned acted as advisor to Ansell Limited for the investment
  • August 2010
    has been acquired by
    The undersigned acted as financial advisor to EnviroLogix, Inc.
  • March 2010
    has been acquired by
    USD$59,000,000
    The undersigned acted as financial advisor to Finnzymes Oy
  • December 2009
    has licensed its ReGet® drug delivery system for ophthalmic indications to
    The undersigned acted as financial advisor to BTG olc
  • October 2009
    has been acquired by
    The undersigned acted as financial advisor to Anaspec Inc.
  • August 2009
    has sold its HySolv™ drug delivery technology to
    The undersigned acted as financial advisor to BTG plc
  • January 2009
    has been acquired by
    The undersigned acted as financial advisor to the shareholders of Labcoat Limited
  • December 2008
    has acquired
    The undersigned is acting as financial advisor to Biocompatibles International
  • December 2008
    has acquired
    The undersigned rendered a Fairness Opinion to Affymetrix, Inc.
  • February 2008
    has been acquired by
    The undersigned is acting as financial advisor to Sigma Pharmaceuticals
  • January 2008
    has been acquired by
    The undersigned is acting as financial advisor to Panbio Limited
  • May 2007
    has acquired
    The undersigned acted as financial advisor to Ansell Limited
  • March 2007
    has sold its Human Health point-of-care diagnostic products business to
    The undersigned acted as financial advisor to Agenix Limited
  • February 2007
    Strategic alliance and investment of up to £32,100,000 in
    The undersigned acted as financial advisor to GeneMedix, PLC
  • December 2006
    Announced M&A advisory and restructuring
    The undersigned acted as financial advisor to Panbio Limited
  • December 2006
    has acquired
    The undersigned acted financial advisor to Novozymes A/S
  • August 2006
    has acquired
    The undersigned acted as financial advisor to Meditech Research Limited
  • July 2006
    has acquired Delta Biotechnology Ltd from
    The undersigned acted as financial advisor to Novozymes A/S
  • April 2006
    has assigned IP and granted distribution rights for its Animal Health business to
    The undersigned acted as financial advisor to Agenix Limited
  • October 2005
    M&A advisory and valuation analysis
    The undersigned acted as financial advisor to CogState Limited
  • September 2005
    NASDAQ listing of ADRs (American Depositary Receipts)
    The undersigned acted as advisor to Genetic Technologies Limited
  • June 2005
    NASDAQ listing of ADRs (American Depositary Receipts)
    The undersigned acted as advisor to ChemGenex Pharmarceuticals Limited
  • January 2005
    awarded to
    for its investment banking role in the creation of
  • December 2004
    has been acquired by
    The undersigned acted as financial advisor to AGT Biosciences Ltd.
Top